PTPN11 and neoplasm: Studies demonstrated that an allosteric PTPN11 inhibitor, RMC-4550, reduced CT26 tumour growth in immunocompetent mice but not in recombinase activating gene 2 (RAG2)-deficient mice, indicating a requirement for adaptive lymphocytes in mediating the protective effect [52].